Phase 1 / 2 Clinical Trial Studying the Safety and Effectiveness of Modakafusp Alfa by Itself and Combined with Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma
Verified

What's the purpose of this trial?

The goal of this clinical trial is to determine the safest and most effective dose of Modakafusp Alfa when given by itself and when combined with Dexamethasone to patients who have relapsed / refractory Multiple Myeloma. 

This trial is currently open and accepting patients.


What will happen during the trial?

This trial is being conducted in three different parts, and Part 3 is currently enrolling. The goal of this part of the trial is to learn if two different doses of Modakafusp Alfa are safe and how well they work in treating relapsed or refractory multiple myeloma. This part of the trial will enroll approximately 236 patients. 

Participants in this part of the trial will receive treatment organized into 28-day cycles and will receive Modakafusp Alfa by intravenous infusion monthly at one of two different doses. This trial is open label, which means that both the participants and health care providers will know which dose they are receiving. 

Participants in this trial may continue to participate as long as they don’t develop bad side effects, and their myeloma doesn’t get worse. 

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

  • Participants must have previously received at least three lines of therapy, including an immunomodulatory agent, proteasome inhibitor, alkylating agent and/or anti-CD38 antibody.
  • Participants must either be refractory or intolerant to at least one immunomodulatory agent and one anti-CD38 antibody.
  • Participants must not have IgM subtype myeloma.
  • Participants must have not received an autologous stem cell transplant in the last 60 days and have not had an allogeneic stem cell transplant in the last 6 months. 
  • Participants must have adequate bone marrow, kidney, liver and cardiac function as described in the clinical protocol. 
  • Participants must not have central nervous system involvement of their myeloma.

Additional Trial Information

Phase 1/2

Enrollment: 336 patients (estimated)

View More

Published Results

MODAKAFUSP ALFA (TAK-573): UPDATED CLINICAL, PHARMACOKINETIC (PK), AND IMMUNOGENICITY RESULTS FROM A PHASE 1/2 STUDY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

June 11, 2022

As of Oct 2021, 30 pts had received modakafusp alfa 1.5 mg/kg Q4W. The median number of prior lines was 7 (range 3–16); 90% of pts were refractory to an anti-CD38 monoclonal antibody (mAb), while 37% were exposed to an anti-B-cell maturation agent (BCMA). Grade (G) 3–4 treatment-emergent adverse events (TEAEs) were reported in 25 pts (83%); the most frequent G3–4 TEAEs were neutropenia in 19 (63%), thrombocytopenia in 13 (43%), leukopenia in 12 (40%), anemia in 9 (30%), and decreased lymphocyte count in 9 (30%) pts. As reported previously, 1 pt in the 1.5 mg/kg Q4W cohort had a G3 bleeding event, while 3 pts had G3 infections. Among all pts, the ORR was 40% (complete response, 7%; very good partial response, 20%; partial response, 13%); among anti-CD38 mAb-refractory and anti BMCA-exposed pts, the ORR was 37% and 27%, respectively. Median progression-free survival was 6 mos and median duration of response had not been reached (Kaplan-Meier estimate, 91% at 6 mos). Based on pooled available data for the Q3W and Q4W cohorts (all doses) within the escalation and expansion phases, there was a strong trend for a dose-exposure-response relationship for ORR, with the apparent inflection point at 1.5 mg/kg Q4W dosing. No apparent relationship between dose-exposure-response and G3/4 thrombocytopenia or neutropenia was observed across all doses, whereas a correlation between dose-exposure-response and incidence of infusion-related reactions across the 0.4–6 mg/kg Q3W and Q4W dosing cohorts was found. There was an apparent non-linear (more than dose proportional) increase in exposure in the dose range of 0.1–3 mg/kg with a geometric mean terminal half-life of 13 hours in serum for modakafusp alfa 1.5 mg/kg. Based on the available data, 14% and 60% of pts were ADA positive at baseline and post-treatment, respectively.

Modakafusp Alfa (TAK-573), an Immunocytokine, Shows Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma; Updated Results from a First-in-Human Phase 1 Study

December 13, 2021

As of May 2021, 83 pts had been treated across all planned dosing schedules. With Q4W dosing, the MTD was exceeded at the 6 mg/kg dose due to DLTs: a grade 3 infusion reaction and prolonged thrombocytopenia and neutropenia, which delayed the start of cycle 2 by >14 days. In total, 24 pts were treated with 1.5 mg/kg modakafusp alfa Q4W (5 pts during dose escalation and 19 pts in an expansion cohort). Analyses include data from all 24 pts. The median number of prior lines of therapy received was 6 (range 4–16); 21 pts (88%) were refractory to an anti-CD38 mAb, and 20 (83%) were triple class-refractory (to a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 mAb). Grade 3 or higher treatment-emergent adverse events (TEAEs) were reported in 18 pts (75%). The most frequent grade 3–4 TEAEs were neutropenia in 12 pts (50%; grade 4 in 6 [25%]), leukopenia in 9 (38%), decreased lymphocyte count in 9 (38%), anemia in 8 (33%), and thrombocytopenia in 8 (33%; grade 4 in 3 [13%]). One pt (4%) had a grade 3 bleeding event and continues on study treatment; 3 pts (13%) had infections (grade 3 in 2 [8%]); and 8 (33%) had infusion reactions (grade 3 in 1 [4%]). The overall response rate (ORR, ≥partial response [PR]) was 42% (complete response [CR], n=2; very good partial response [VGPR], n=5; PR, n=3), and the clinical benefit rate (ORR + minimal response [MR]) was 54% (MR, n=3). Median progression-free survival was 5.7 months (95% confidence interval [CI], 1.9–not reached [NR]), median time to response was 1.9 months (95% CI, 0.95–NR), and median duration of response was 7.4 months (95% CI, 2.3–NR). Among the 21 anti-CD38 mAb-refractory pts, the ORR was 43%, while among the 4 pts who received an anti-CD38 mAb in their most recent line of therapy prior to enrollment, the ORR was 75% (CR, n=1; VGPR, n=2). Correlative studies show evidence of T-cell and natural killer-cell activation, as well as activation of IFN signaling in CD38+ cells, including upregulation of CD38 expression.

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

Arkansas

Highlands Oncology Group

Springdale, AR

Open and Accepting

California

Glendale Adventist Health Medical Center

Glendale, CA

Open and Accepting

James R Berenson, MD, Inc.

West Hollywood, CA

Open and Accepting

Connecticut

Yale Cancer Center Smilow Cancer Hospital at Yale-New Haven

New Haven, CT

Not Yet Accepting

Georgia

Winship Cancer Institute of Emory University

Atlanta, GA

Open and Accepting

Illinois

Northwestern University Feinberg School of Medicine

Chicago, IL

Not Yet Accepting

Loyola University Medical Center Cardinal Bernardin Cancer Center

Maywood, IL

Not Yet Accepting

Maryland

Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Medicine

Baltimore, MD

Not Yet Accepting

Massachusetts

Boston Medical Center

Boston, MA

Not Yet Accepting

Dana-Farber Cancer Institute

Boston, MA

Open and Accepting

Nebraska

Nevada

Comprehensive Cancer Centers of Nevada (Central Valley)

Las Vegas, NV

Open and Accepting

New Jersey

John Theurer Cancer Center Hackensack Meridian Health

Hackensack, NJ

Open and Accepting

New York

Montefiore Medical Center

Bronx, NY

Not Yet Accepting

Roswell Park Cancer Institute

Buffalo, NY

Not Yet Accepting

University of Rochester Medical Center James P. Wilmot Cancer Center

Rochester, NY

Not Yet Accepting

North Carolina

Levine Cancer Institute Atrium Health

Charlotte, NC

Open and Accepting

Duke Cancer Center Duke University Medical Center

Durham, NC

Not Yet Accepting

Ohio

Gabrail Cancer Center Research

Canton, OH

Open and Accepting

Oregon

Oregon Health and Science University (OHSU) Knight Cancer Institute

Portland, OR

Not Yet Accepting

Pennsylvania

Abramson Cancer Center University of Pennsylvania

Philadelphia, PA

Open and Accepting

Utah

Huntsman Cancer Institute University of Utah

Salt Lake City, UT

Not Yet Accepting

Wisconsin

UW Carbone Cancer Center University of Wisconsin Health

Madison, WI

Not Yet Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with Takeda Oncology to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors